Viking Therapeutics Inc (VKTX)
51.66
+0.13
(+0.25%)
USD |
NASDAQ |
Nov 21, 16:00
51.96
+0.30
(+0.58%)
After-Hours: 20:00
Viking Therapeutics Net Income (Quarterly): -24.94M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -24.94M |
| June 30, 2024 | -22.25M |
| March 31, 2024 | -27.36M |
| December 31, 2023 | -24.60M |
| September 30, 2023 | -22.53M |
| June 30, 2023 | -19.22M |
| March 31, 2023 | -19.53M |
| December 31, 2022 | -19.56M |
| September 30, 2022 | -15.77M |
| June 30, 2022 | -17.43M |
| March 31, 2022 | -16.10M |
| December 31, 2021 | -12.36M |
| September 30, 2021 | -13.24M |
| June 30, 2021 | -15.38M |
| March 31, 2021 | -14.01M |
| December 31, 2020 | -10.95M |
| September 30, 2020 | -9.288M |
| June 30, 2020 | -9.572M |
| March 31, 2020 | -9.687M |
| December 31, 2019 | -7.45M |
| September 30, 2019 | -5.731M |
| June 30, 2019 | -7.674M |
| March 31, 2019 | -4.924M |
| Date | Value |
|---|---|
| December 31, 2018 | -5.24M |
| September 30, 2018 | -6.60M |
| June 30, 2018 | -6.672M |
| March 31, 2018 | -3.551M |
| December 31, 2017 | -4.085M |
| September 30, 2017 | -6.099M |
| June 30, 2017 | -5.172M |
| March 31, 2017 | -5.222M |
| December 31, 2016 | -3.645M |
| September 30, 2016 | -3.807M |
| June 30, 2016 | -3.693M |
| March 31, 2016 | -3.587M |
| December 31, 2015 | -5.091M |
| September 30, 2015 | -4.736M |
| June 30, 2015 | -7.865M |
| March 31, 2015 | -5.711M |
| December 31, 2014 | 1.389M |
| September 30, 2014 | -0.2618M |
| June 30, 2014 | -22.78M |
| March 31, 2014 | -0.2289M |
| June 30, 2013 | -0.0224M |
| March 31, 2013 | -0.0046M |
| December 31, 2012 | -0.111M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-27.36M
Minimum
Mar 2024
-7.45M
Maximum
Dec 2019
-16.56M
Average
-15.94M
Median
Net Income (Quarterly) Benchmarks
| Amgen Inc | 2.83B |
| Eli Lilly and Co | 970.30M |
| Pfizer Inc | 4.465B |
| Structure Therapeutics Inc | -33.98M |
| Altimmune Inc | -22.84M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 36.56M |
| EPS Diluted (Quarterly) | -0.22 |
| Enterprise Value | 4.812B |
| Earnings Yield | -1.80% |